A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer

被引：0

作者：

Church, David N. ^{[1
]}

Price, Chris G. A. ^{[2
]}

机构：

[1] Univ Oxford, John Racliffe Hosp, Weatherall Inst Mol Med, Headley Way, Oxford OX3 9DS, England

[2] Bristol Haematol & Oncol Ctr, Bristol BS1 8ED, Avon, England

来源：

CLINICAL MEDICINE INSIGHTS-THERAPEUTICS | 2009年 / 1卷

关键词：

breast cancer; trastuzumab; metastatic; ERBB2; HER2;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The ERBB2 or HER2 receptor is overexpressed in 25% of breast cancers and is associated with poor prognosis. Trastuzumab, a monoclonal antibody targeting HER2 has been demonstrated to improve survival when combined with chemotherapy for the treatment of HER2 overexpressing metastatic breast cancer (MBC). Further studies have endeavoured to clarify the optimum chemotherapy regimen in combination with trastuzumab for MBC and its use together with novel biological agents. This review summarises these data together with preclinical studies exploring the mechanism of trastuzumab action and causes of drug resistance. The frequent incidence of brain metastases in patients on trastuzumab is highlighted, and data on the continuation of trastuzumab following CNS and non-CNS progression reviewed.

引用

页码：557 / 570

页数：14

共 149 条

[51]

Fountzilas George, 2003, Clin Breast Cancer, V4, P120, DOI 10.3816/CBC.2003.n.017

[52] The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy [J].

Fox, K. F. .

BRITISH JOURNAL OF CANCER, 2006, 95 (10) :1454-1454

[53] PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer [J].

Fujita, T ;

Doihara, H ;

Kawasaki, K ;

Takabatake, D ;

Takahashi, H ;

Washio, K ;

Tsukuda, K ;

Ogasawara, Y ;

Shimizu, N .

BRITISH JOURNAL OF CANCER, 2006, 94 (02) :247-252

[54] The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors [J].

Garrett, TPJ ;

McKern, NM ;

Lou, MZ ;

Elleman, TC ;

Adams, TE ;

Lovrecz, GO ;

Kofler, M ;

Jorissen, RN ;

Nice, EC ;

Burgess, AW ;

Ward, CW .

MOLECULAR CELL, 2003, 11 (02) :495-505

[55] Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines [J].

Gaul, MD ;

Guo, Y ;

Affleck, K ;

Cockerill, GS ;

Gilmer, TM ;

Griffin, RJ ;

Guntrip, S ;

Keith, BR ;

Knight, WB ;

Mullin, RJ ;

Murray, DM ;

Rusnak, DW ;

Smith, K ;

Tadepalli, S ;

Wood, ER ;

Lackey, K .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (04) :637-640

[56]

GELMON KA, 2004, CLIN BREAST CANCER, V5, P59

[57]

Gelmon KA, 2004, CLIN BREAST CANCER, V5

[58]

Gelmon Karen A, 2004, Clin Breast Cancer, V5, P52, DOI 10.3816/CBC.2004.n.010

[59] Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 [J].

Gennari, R ;

Menard, S ;

Fagnoni, F ;

Ponchio, L ;

Scelsi, M ;

Tagliabue, E ;

Castiglioni, F ;

Villani, L ;

Magalotti, C ;

Gibelli, N ;

Oliviero, B ;

Ballardini, B ;

Da Prada, G ;

Zambelli, A ;

Costa, A .

CLINICAL CANCER RESEARCH, 2004, 10 (17) :5650-5655

[60] Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J].

Geyer, Charles E. ;

Forster, John ;

Lindquist, Deborah ;

Chan, Stephen ;

Romieu, C. Gilles ;

Pienkowski, Tadeusz ;

Jagiello-Gruszfeld, Agnieszka ;

Crown, John ;

Chan, Arlene ;

Kaufman, Bella ;

Skarlos, Dimosthenis ;

Campone, Mario ;

Davidson, Neville ;

Berger, Mark ;

Oliva, Cristina ;

Rubin, Stephen D. ;

Stein, Steven ;

Cameron, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) :2733-2743

← 1 2 3 4 5 6 7 8 9 10 →